Clinical Efficacy On Jiawei Sangbaipi Decoction In Treating Aecopd With Phlegm Heat And Blood Stasis Type And Its Influence On HMGB1and FIB

Objective:The aim of the study was to assess the clinical effect of Jiawei Sangbaipi decoction in the treatment of AECOPD patients who were phlegm heat and blood stasis type by a randomized controlled clinical trial design,which affected the clinical symptom,sign,serum high mobility group protein B1(HMGB1) and plasma fibrinogen (FIB)changes.Methods:According to inclusion criterion,60AECOPD patients with phlegm heat and blood stasis type in TCM form January2013to January2014in our hospital were randomly divided into two groups, the trial group and the control group.The patients of control group only take conventional therapy of the western medicine,such as oxygen treatment,antibiotic, expectorants, bronchodilators. The patients of trial group treaded with Jiawei Sangbaipi decoction and western medicine.The period of treatment is10days.TO compare the result of two groups by analyzing clinical symptom and sign, the level of serum HMGB1and plasma FIB. All the data were analyzed by statistical software SPSS18.0.Result:1.The curative effect:The tole effective rate of the trial group and the control group were96.67%and86.67%respectively, the trial group was superior to the control group in the curative effect(P<0.05).It indicated that Jiawei Sangbaipi decoction could improve the curative effect of AECOPD.2.Clinical symptom and sign: After treatment, melioration of clinical symptom and sign in both groups have significant difference(P<0.05).Compared with the control group, the trial group was superior to the control group in the relieving of syndrome and sign, such as wheeze,cough,the volume of phlegm and the properties of phlegm (P<0.05),but there were not significant differences between the two groups in fever, pulmonary rales, cyanotic in lips and nails and chest pain(P>0.05).3.Serum HMGB1and plasma FIB:After treatment, the decrease degree of HMGB1and FIB have significant difference in both groups(P<0.05). Compared with the control group,the trial group’s level of HMGB1and FIB were lower than the controlled group(P<0.05).It indicated that Jiawei Sangbaipi decoction can significantly decrease the level of HMGB1and FIB.4.Changes of HMGB1, FIB in different levels of COPD:compared within group, the changes of HMGB1and FIB were not significant differences in different levels of COPD(P>0.05). It indicated that There were no significant differences in the Changes of HMGB1and FIB between the moderate and severe of COPD.5.There was no serious adverse effects in both groups,which indicated that it was safe in conventional therapy of western medicine cooperated with Jiawei Sangbaipi decoction.Conclusion:l.The curative effect of conventional therapy of western medicine cooperated with Jiawei Sangbaipi decoction in treating AECOPD is superior to conventional therapy of western medicine. Jiawei Sangbaipi decoction can relieve the clinical symptom and sign,such as wheeze,cough, the volume of phlegm and the properties of phlegm.2.Jiawei Sangbaipi decoction can reduce the level of HMGB1and FIB of AECOPD. There were no significant differences in the Changes of HMGB1and FIB between the moderate and severe of COPD.3.Jiawei Sangbaipi decoction in the treatment of AECOPD have no obvious adverse reaction and side effect.So that it is safe to use in clinic.